In vitro and in vivo amelioration of colitis using targeted delivery system of cyclosporine a in New Zealand rabbits

2020 ◽  
Vol 46 (10) ◽  
pp. 1726-1733
Author(s):  
Sumit Sharma ◽  
Vivek Rajan Sinha
Nanoscale ◽  
2020 ◽  
Vol 12 (32) ◽  
pp. 17029-17044
Author(s):  
Li Xiao ◽  
Yang Hou ◽  
Huimin He ◽  
Sinan Cheng ◽  
Yifan Hou ◽  
...  

HCSP4-Lipo-DOX-miR101 is a novel and efficient approach for HCC targeted therapy with MDR inhibition in vitro and in vivo.


2015 ◽  
Vol 24 (4) ◽  
pp. 359-371 ◽  
Author(s):  
Wei Fan ◽  
Xiang Wang ◽  
Baoyue Ding ◽  
Haimin Cai ◽  
Xudong Wang ◽  
...  

RSC Advances ◽  
2016 ◽  
Vol 6 (69) ◽  
pp. 64306-64314 ◽  
Author(s):  
M. H. Han ◽  
Z. T. Li ◽  
D. D. Bi ◽  
Y. F. Guo ◽  
H. X. Kuang ◽  
...  

Cholesterol-PEG1000-FA (folic acid) was synthesized as a stabilizer to encapsulate DTX, for the construction of a promising targeted delivery system for breast cancer therapy.


Pharmaceutics ◽  
2018 ◽  
Vol 10 (4) ◽  
pp. 285 ◽  
Author(s):  
Malika Lahiani-Skiba ◽  
Francois Hallouard ◽  
Frederic Bounoure ◽  
Nicolas Milon ◽  
Youness Karrout ◽  
...  

Cyclosporine (CsA) has a selective property of suppressing various T-lymphocyte functions. This is of utmost importance in preventing allograft rejection by several organ transplantations, as well as in the treatment of systemic and local autoimmune disorders. However, the poor water solubility of CsA can be a major hurdle for its absorption into the blood stream, which leads to low bioavailability and thus less efficacy. The aim of this study was to prepare, characterize, and evaluate in vitro as well as in vivo, the potential of the innovative CsA drug delivery system. The latter contains CsA in spherical amorphous solid dispersion (SASD) which is embedded in an original α-cyclodextrin and β-cyclodextrin polymer mixture (Poly-αβ-CD) as a multifunctional amorphous carrier. The new developed SASD formulation showed that CsA was molecularly dispersed in αβ-cyclodextrins in an amorphous form, as was confirmed by physicochemical characterization studies. Interestingly, the peptide secondary structure, and thus, the drug activity was not impacted by the preparation of SASD as was shown by circular dichroism. Furthermore, the in vitro CsA release profile kinetics was almost identical to the commercially available product Neoral®. This study presents the first in vivo proof-of-concept for a novel drug delivery system based on Poly-αβ-CD containing CsA, with SASD allowing for increased bioavailibility. The pharmacokinetic parameters of cyclosporine A from the spherical spray-dried dispersion formulation was demonstrated in a “rat” animal model. For comparison, the commercially available Neoral® was studied. Importantly, the pharmacokinetic parameters were improved by extending Tmax from 2 to 3 h after the oral administration in rats, and eventually preventing the enterohepatic circulation. All these results clearly demonstrate the improved pharmacokinetic parameters and enhanced bioavailability of CsA in the new developed drug delivery system. These data demonstrated the superiority of the newly developed Poly-αβ-CD formulation for oral administration of the poorly soluble CsA in vivo without altering its secondary structure. Poly-αβ-CD can be a very useful tool for the oral administration of poorly water-soluble drugs.


2014 ◽  
Vol 2014 ◽  
pp. 1-23 ◽  
Author(s):  
Su-Eon Jin ◽  
Hyo-Eon Jin ◽  
Soon-Sun Hong

Targeted delivery systems of nanobiomaterials are necessary to be developed for the diagnosis and treatment of cancer. Nanobiomaterials can be engineered to recognize cancer-specific receptors at the cellular levels and to deliver anticancer drugs into the diseased sites. In particular, nanobiomaterial-based nanocarriers, so-called nanoplatforms, are the design of the targeted delivery systems such as liposomes, polymeric nanoparticles/micelles, nanoconjugates, norganic materials, carbon-based nanobiomaterials, and bioinspired phage system, which are based on the nanosize of 1–100 nm in diameter. In this review, the design and the application of these nanoplatforms are discussed at the cellular levels as well as in the clinics. We believe that this review can offer recent advances in the targeted delivery systems of nanobiomaterials regardingin vitroandin vivoapplications and the translation of nanobiomaterials to nanomedicine in anticancer therapy.


1999 ◽  
Vol 57 (1) ◽  
pp. 45-53 ◽  
Author(s):  
Takashi Ishibashi ◽  
Harumi Hatano ◽  
Masao Kobayashi ◽  
Masakazu Mizobe ◽  
Hiroyuki Yoshino

Sign in / Sign up

Export Citation Format

Share Document